Stefania Mantovani

List of Publications by Year
in descending order

62 papers	4,474 citations	159358 30 h-index	133063 59 g-index
67 all docs	67 docs citations	67 times ranked	9521 citing authors

#	Article	IF	Citations
1	Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity. Human Genetics, 2022, 141, 147-173.	1.8	22
2	The polymorphism L412F in <i>TLR3</i> inhibits autophagy and is a marker of severe COVID-19 in males. Autophagy, 2022, 18, 1662-1672.	4.3	25
3	MICA/B-targeted antibody promotes NK cellâ€"driven tumor immunity in patients with intrahepatic cholangiocarcinoma. OncoImmunology, 2022, 11, 2035919.	2.1	13
4	Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients. Genes and Immunity, 2022, 23, 51-56.	2.2	41
5	Adaptive Natural Killer Cell Functional Recovery in Hepatitis C Virus Cured Patients. Hepatology, 2021, 73, 79-90.	3.6	15
6	Unique immunological profile in patients with COVID-19. Cellular and Molecular Immunology, 2021, 18, 604-612.	4.8	181
7	Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research. European Journal of Human Genetics, 2021, 29, 745-759.	1.4	35
8	EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count. International Journal of Infectious Diseases, 2021, 104, 315-319.	1.5	66
9	Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males. EBioMedicine, 2021, 65, 103246.	2.7	52
10	Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study. ELife, 2021, 10, .	2.8	145
11	Protective Role of a TMPRSS2 Variant on Severe COVID-19 Outcome in Young Males and Elderly Women. Genes, 2021, 12, 596.	1.0	39
12	C9orf72 Intermediate Repeats Confer Genetic Risk for Severe COVID-19 Pneumonia Independently of Age. International Journal of Molecular Sciences, 2021, 22, 6991.	1.8	12
13	A new algorithm shows superior ability to discriminate liver fibrosis stages in chronic hepatitis C. Journal of Viral Hepatitis, 2021, 28, 1443-1451.	1.0	1
14	Mapping the human genetic architecture of COVID-19. Nature, 2021, 600, 472-477.	13.7	640
15	Genetic mechanisms of critical illness in COVID-19. Nature, 2021, 591, 92-98.	13.7	1,014
16	High Frequencies of Functional Virus-Specific CD4+ T Cells in SARS-CoV-2 Subjects With Olfactory and Taste Disorders. Frontiers in Immunology, 2021, 12, 748881.	2.2	11
17	ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population. European Journal of Human Genetics, 2020, 28, 1602-1614.	1.4	208
18	An Anti-MICA/B Antibody and IL-15 Rescue Altered NKG2D-Dependent NK Cell Responses in Hepatocellular Carcinoma. Cancers, 2020, 12, 3583.	1.7	16

#	Article	IF	Citations
19	Expansion of atypical memory B cells is a prominent feature of COVID-19. Cellular and Molecular Immunology, 2020, 17, 1101-1103.	4.8	76
20	Detection of the SARSâ€CoVâ€2 in different biologic specimens from positive patients with COVIDâ€19, in Northern Italy. Pediatric Allergy and Immunology, 2020, 31, 72-74.	1.1	4
21	Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE). Microorganisms, 2020, 8, 695.	1.6	186
22	Emergency Department and Out-of-Hospital Emergency System (112â€"AREU 118) integrated response to Coronavirus Disease 2019 in a Northern Italy centre. Internal and Emergency Medicine, 2020, 15, 825-833.	1.0	50
23	SARS Cov-2 infection in a renal-transplanted patient: A case report. American Journal of Transplantation, 2020, 20, 1882-1884.	2.6	76
24	Natural Killer Cell Responses in Hepatocellular Carcinoma: Implications for Novel Immunotherapeutic Approaches. Cancers, 2020, 12, 926.	1.7	42
25	Severe acute respiratory syndrome coronavirus 2 RNA contamination of inanimate surfaces and virus viability in a health care emergency unit. Clinical Microbiology and Infection, 2020, 26, 1094.e1-1094.e5.	2.8	121
26	Clinical and molecular characterization of COVID-19 hospitalized patients. PLoS ONE, 2020, 15, e0242534.	1.1	25
27	Human Monoclonal Antibodies as Adjuvant Treatment of Chronic Hepatitis B Virus Infection. Frontiers in Immunology, 2019, 10, 2290.	2.2	5
28	Decreased interferonâ€Î³ production by NK cells from KIR haplotype B carriers in hepatitis C virus infection. Liver International, 2019, 39, 1237-1245.	1.9	3
29	THU-482-A human anti-MICA/B antibody boost NK cell responses in hepatocellular carcinoma. Journal of Hepatology, 2019, 70, e373.	1.8	1
30	Deficient Natural Killer Cell NKp30â€Mediated Function and Altered NCR3 Splice Variants in Hepatocellular Carcinoma. Hepatology, 2019, 69, 1165-1179.	3.6	48
31	Altered natural killer cell cytokine profile in type 2 autoimmune hepatitis. Clinical Immunology, 2018, 188, 31-37.	1.4	8
32	Defective NKp30-mediated function in hepatocellular carcinoma-infiltrating NK cells. Journal of Hepatology, 2018, 68, S679-S680.	1.8	2
33	Defective DNAM-1 mediated cytotoxicity in NK cells infiltrating hepatocellular carcinoma. Journal of Hepatology, 2018, 68, S667.	1.8	0
34	Hepatitis C virus-induced NK cell activation causes metzincin-mediated CD16 cleavage and impaired antibody-dependent cytotoxicity. Journal of Hepatology, 2017, 66, 1130-1137.	1.8	32
35	Monocytes inhibit hepatitis C virus-induced TRAIL expression on CD56bright NK cells. Journal of Hepatology, 2017, 67, 1148-1156.	1.8	20
36	Hepatitis C virus inhibits CD4 T cell function via binding to Toll-like receptor 7. Antiviral Research, 2017, 137, 108-111.	1.9	16

#	Article	IF	Citations
37	Lack of Siglec-7 expression identifies a dysfunctional natural killer cell subset associated with liver inflammation and fibrosis in chronic HCV infection. Gut, 2016, 65, 1998-2006.	6.1	50
38	<scp>NK</scp>p30 isoforms in patients with chronic hepatitis C virus infection. Immunology, 2015, 146, 234-242.	2.0	23
39	Skewed B cells in chronic hepatitis C virus infection maintain their ability to respond to virusâ€induced activation. Journal of Viral Hepatitis, 2015, 22, 391-398.	1.0	34
40	FcÎ³RIIIa shedding from NK cells does not impair antibody-dependent cellular cytotoxicity in chronic HCV infection. Digestive and Liver Disease, 2014, 46, e49.	0.4	0
41	P124 MATRIX METALLOPROTEINASE (MMP)-DEPENDENT SHEDDING REDUCES NK CELL FcgRIIIa EXPRESSION IN CHRONIC HCV INFECTION WITHOUT AFFECTING THE EFFICIENCY OF ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY. Journal of Hepatology, 2014, 60, S107.	1.8	0
42	Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection. Journal of Hepatology, 2013, 59, 38-44.	1.8	52
43	Natural killer cell functional dichotomy: a feature of chronic viral hepatitis?. Frontiers in Immunology, 2012, 3, 351.	2.2	29
44	Impaired intrahepatic natural killer cell cytotoxic function in chronic hepatitis C virus infection. Hepatology, 2012, 56, 841-849.	3.6	94
45	Amyotrophic Lateral Sclerosis Multiprotein Biomarkers in Peripheral Blood Mononuclear Cells. PLoS ONE, 2011, 6, e25545.	1.1	123
46	Repeated courses of granulocyte colonyâ€stimulating factor in amyotrophic lateral sclerosis: Clinical and biological results from a prospective multicenter study. Muscle and Nerve, 2011, 43, 189-195.	1.0	64
47	Nitroproteomics of Peripheral Blood Mononuclear Cells from Patients and a Rat Model of ALS. Antioxidants and Redox Signaling, 2009, 11, 1559-1567.	2.5	35
48	Immune system alterations in sporadic amyotrophic lateral sclerosis patients suggest an ongoing neuroinflammatory process. Journal of Neuroimmunology, 2009, 210, 73-79.	1.1	156
49	An in vitro model of T cell receptor revision in mature human CD8+ T cells. Molecular Immunology, 2008, 45, 328-337.	1.0	17
50	Melanocyte-specific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity?. Pigment Cell & Melanoma Research, 2005, 18, 234-242.	4.0	41
51	Qualitative difference between the cytotoxic Tâ€„lymphocyte responses to melanocyte antigens in melanoma and vitiligo. European Journal of Immunology, 2005, 35, 3153-3162.	1.6	32
52	Transfer of efficient anti-melanocyte T cells from vitiligo donors to melanoma patients as a novel immunotherapeutical strategy. Journal of Autoimmune Diseases, 2005, 2, 7.	1.0	4
53	Molecular and Functional Bases of Self-Antigen Recognition in Long-Term Persistent Melanocyte-Specific CD8+ T Cells in One Vitiligo Patient. Journal of Investigative Dermatology, 2003, 121, 308-314.	0.3	28
54	Analysis of Secondary V(D)J Rearrangements in Mature, Peripheral T Cells of Ataxia-Telangiectasia Heterozygotes. Laboratory Investigation, 2003, 83, 1467-1475.	1.7	16

#	Article	IF	Citations
55	Dominant TCR-Î± Requirements for a Self Antigen Recognition in Humans. Journal of Immunology, 2002, 169, 6253-6260.	0.4	40
56	Human CD8 coâ€“receptor is strictly involved in MHCâ€“peptide tetramerâ€“TCR binding and T cell activation. International Immunology, 2002, 14, 39-44.	1.8	41
57	Cytotoxic T-lymphocyte responses in melanoma through in vitro stimulation with the Melan-A peptide analogue A27L: a qualitative analysis. Melanoma Research, 2002, 12, 491-498.	0.6	7
58	Specific Cytotoxic T Lymphocyte Responses Against Melan-A/MART1, Tyrosinase and Gp100 in Vitiligo by the Use of Major Histocompatibility Complex/Peptide Tetramers: the Role of Cellular Immunity in the Etiopathogenesis of Vitiligo. Journal of Investigative Dermatology, 2001, 117, 326-332.	0.3	173
59	Kinetics of GATA-3 gene expression in early polarizing and committed human T cells. Immunology, 2001, 102, 123-130.	2.0	36
60	Diverse expansion potential and heterogeneous avidity in tumor-associated antigen-specific T lymphocytes from primary melanoma patients. European Journal of Immunology, 2001, 31, 412-420.	1.6	38
61	Increased frequency of RAG-expressing, CD4+CD3low peripheral T lymphocytes in patients with defective responses to DNA damage. European Journal of Immunology, 2000, 30, 1520-1525.	1.6	24
62	Cutting Edge: Recombinase-Activating Gene Expression and V(D)J Recombination in CD4+CD3low Mature T Lymphocytes. Journal of Immunology, 2000, 164, 3455-3459.	0.4	40